Paxlovid as a potential treatment for long COVID

Area of Science:

• Public Health
• Infectious Diseases
• Clinical Research

Background:

• Millions of Americans experience long COVID, a condition with over 200 symptoms affecting multiple body systems.
• Currently, no FDA-approved treatments exist for long COVID, highlighting an urgent need for therapeutic options.
• The RECOVER Initiative is a major research platform dedicated to understanding and treating long COVID.

Purpose of the Study:

• To evaluate the efficacy of nirmatrelvir/ritonavir (Paxlovid) as a treatment for long COVID.
• To explore the potential of antiviral agents in managing persistent symptoms following SARS-CoV-2 infection.
• To provide the first prospective, randomized study data on Paxlovid for long COVID within the RECOVER initiative.

Main Methods:

• The RECOVER-Vital study is a prospective, randomized clinical trial.
• Enrollment is open for participants in the RECOVER-Vital study.
• The study will assess the SARS-CoV-2 antiviral nirmatrelvir/ritonavir (Paxlovid).

Main Results:

• This manuscript explores existing knowledge on Paxlovid for long COVID.
• The rationale for using an antiviral agent to treat long COVID is examined.
• Specific results from the RECOVER-Vital trial are pending.

Conclusions:

• Further research is needed to establish effective treatments for long COVID.
• Paxlovid is being investigated as a potential therapeutic option for long COVID.
• The RECOVER Initiative is advancing the scientific understanding and treatment of long COVID.